Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker

Ru Wang; Xiao Li; Huimin Zhang; Ke Wang; Jianjun He

doi:10.18632/oncotarget.20608

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker

Ru Wang, Xiao Li, Huimin Zhang, Ke Wang and Jianjun He _

PDF | HTML | How to cite

Oncotarget. 2017; 8:75742-75755. https://doi.org/10.18632/oncotarget.20608

Metrics: PDF 2168 views | HTML 4277 views | ?

Abstract

Ru Wang1, Xiao Li1, Huimin Zhang1, Ke Wang1 and Jianjun He1

1Department of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, P.R. China

Correspondence to:

Jianjun He, email: [email protected]

Keywords: biomarker, liquid biopsy, ctDNA, breast cancer

Received: May 09, 2017 Accepted: August 17, 2017 Published: September 01, 2017

ABSTRACT

Circulating tumor DNA (ctDNA) in the blood of cancer patients contains much information on genetic and epigenetic profiles associated with cancer development, progression, and response to therapy. Analysis of ctDNA provides an opportunity for non-invasive sampling of tumor DNA repetitiously and therefore advance precision medicine. Recent development in massively parallel sequencing and digital genomic techniques support the analytical and clinical validity of ctDNA as a promising ‘liquid biopsy’ in human cancer. In this review, we discussed the current status of cell-free ctDNA including ctDNA biology, recently developed techniques for ctDNA detection, breast cancer specific detecting strategies, with a focus on clinical applications of ctDNA-based biomarkers in breast oncology.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20608

Publication Alerts

Reviews:

Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker

Abstract